Thoughts on Merchant Group establishing a dedicated $250m biotech fund. Andrew Chapman and co have a pretty solid record when it comes to investing in early-stage biotechs.
A dedicated biotech fund taking a position in UBI could be extremely favourable. They'd be particularly interested in UBI's ability to develop rapid cancer detection from a single drop of blood.
https://www.swinburne.edu.au/news/2021/08/researchers-work-to-develop-rapid-cancer-detection-from-a-single-drop-of-blood/
https://www.copyright link/street-talk/merchant-buying-into-biotech-boom-with-250m-fund-20210702-p586f4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.172M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| UBI (ASX) Chart |
Day chart unavailable